PerkinElmer Inc (PKI.N) agreed to purchase Caliper Life Sciences Inc (CALP.O) for $600 million to broaden its product offerings in molecular imaging and genomic detection technologies. The deal marks the biggest acquisition for PerkinElmer under Robert Friel, who became its chief executive in 2008. PerkinElmer, which sells scientific instruments, environmental safety monitoring products and medical testing equipment, said on Thursday it would pay $10.50 per share for Caliper, which represents a 42 percent premium over its Wednesday closing share price of $7.39 on Wednesday. Caliper shares jumped 41 percent to $10.39 on Nasdaq, while PerkinElmer shares were down nearly 3 percent at $21.40 on the New York Stock Exchange..
PerkinElmer, Inc. is a provider of technology, services and solutions to the diagnostics, research, environmental and safety, industrial and laboratory services markets. Shares of PKI fell by 3.13% or $-0.69/share to $21.36. In the past year, the shares have traded as low as $20.67 and as high as $28.75. On average, 1159200 shares of PKI exchange hands on a given day and today's volume is recorded at 1437923.
Caliper Life Sciences, Inc. (Caliper) develops and sells products and services to the life sciences research community, a customer base that includes pharmaceutical and biotechnology companies, and government and other research institutions. Shares of CALP traded higher by 40.87% or $3.02/share to $10.41. In the past year, the shares have traded as low as $3.31 and as high as $8.68. On average, 403535 shares of CALP exchange hands on a given day and today's volume is recorded at 41905800.
Source
